Trials / Unknown
UnknownNCT05065398
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
An Open Label， Multicenter Phase II Clinical Trial to Evaluate the Efficacy，Safety and Pharmacokinetics of HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy，safety and pharmacokinetics of HLX208 in advanced non-small cell lung cancer patients with BRAF V600 mutation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX208 | 450mg bid, take orally |
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2023-06-30
- Completion
- 2023-12-30
- First posted
- 2021-10-04
- Last updated
- 2022-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05065398. Inclusion in this directory is not an endorsement.